Antiarrhythmic effects of the thromboxane antagonist BM 13.177.
The effects of the thromboxane antagonist BM 13.177 (5 mg kg-1 + 0.15 mg kg-1 min-1) was investigated on the ventricular arrhythmias that result from coronary artery occlusion and reperfusion in anaesthetised open-chest greyhounds. BM 13.177 markedly reduced the severity and incidence of arrhythmias resulting from ischaemia; the number of ventricular ectopic beats was reduced from 1,084 +/- 159 (in controls) to 544 +/- 179 (in dogs given BM 13.177) and the incidences of ventricular tachycardia (VT) and ventricular fibrillation (VF) were reduced from 86 to 22% and from 30 to 10% respectively. Following reperfusion the incidence of VF was 86% in controls and 44% in dogs given BM 13.177. Thus the total incidence of VF during the combined ischaemia-reperfusion insult was significantly reduced by treatment with BM 13.177 from 90% (in control dogs) to 50%. These results lend further support to the hypothesis that thromboxane is involved in the genesis of arrhythmias and that blockade of thromboxane receptors may be a suitable approach to antiarrhythmic therapy under conditions of ischaemia and reperfusion.
D000818:Animals; D000889:Anti-Arrhythmia Agents; D001145:Arrhythmias, Cardiac / Q000517:prevention & control*; D002245:Carbon Dioxide / Q000097:blood; D003327:Coronary Disease / Q000150:complications / Q000188:drug therapy; D004285:Dogs; D006439:Hemodynamics / Q000187:drug effects; D010100:Oxygen / Q000097:blood; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*; D013931:Thromboxanes / Q000037:antagonists & inhibitors*
D000889:Anti-Arrhythmia Agents; D013449:Sulfonamides; D013931:Thromboxanes; D002245:Carbon Dioxide; C040624:sulotroban; D010100:Oxygen